Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 2, 1999, Pages 798-804

  Chopin, Philippe ^a   Colpaert, Francis C ^a   Marien, Marc ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; APOMORPHINE; BRIMONIDINE; CLONIDINE; EFAROXAN; IDAZOXAN; METHYLPHENIDATE; OXIDOPAMINE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ALPHA ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; BENZOFURANS; CLONIDINE; DOPAMINE AGONISTS; IDAZOXAN; IMIDAZOLES; LIGANDS; MALE; METHYLPHENIDATE; OXIDOPAMINE; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; STEREOISOMERISM; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA;

EID: 0033064450     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Antelman SM and Caggiula AR (1994) Norepinephrine-dopamine interactions: One step beyond, in Noradrenergic Mechanisms in Parkinson's Disease (Briley M and Marien M eds) pp 127-138, CRC Press, Boca Raton.
2. Armah BI (1988) Unique presynaptic alpha-2 receptor selectivity and specificity of the antihypertensive agent moxonidine. Arzneim Forsch 38:1435-1442.
3. Arnt J (1987) Behavioural studies of dopamine receptors: Evidence for regional selectivity and receptor multiplicity, in Dopamine Receptors (Creese I and Fraser CA eds) pp 199-231, Alan Liss, New York.
4. 2-Adrenergic agonists reduce glutamate release and glutamate receptor-mediated calcium changes in hippocampal slices during hypoxia. Neuropharmacology 35: 679-687.
5. 2-receptors in the hypothermia induced by clonidine in the rat. Neuropharmacology 19:9-15.
6. Bylund DB (1995) Pharmacological characteristics of alpha-2 adrenergic receptor subtypes. Ann NY Acad Sci 763:1-7.
7. Bylund DB, Blaxall HS, Iversen LJ, Caron MG, Lefkpwitz RJ and Lomasney JW (1992) Pharmacological characteristics of alpha-2 adrenergic receptors: Comparison of pharmacologically defined subtypes with subtypes identified with molecular cloning. Mol Pharmacol 42:1-5.
8. Carlisle MA, Smyth DD and Glavin GB (1995) Efaroxan acts peripherally to block the antisecretory and gastroprotective effects of moxonidine in rats. J Pharmacol Exp Ther 274:598-601.
9. Carman LS, Gage FH and Shults CW (1991) Partial lesion of the substantia nigra: Relation between extent of lesion and rotational behavior. Brain Res 553:275-283.
10. Cash R, Ruberg M, Raisman R and Agid Y (1984) Adrenergic receptors in Parkinson's disease. Brain Res 322:269-275.
11. Collingridge GL, James TA and MacCleod NK (1979) Neurochemical and electrophysiological evidence for a projection from the locus coeruleus to the substantia nigra. J Physiol 290:44.
12. Colpaert FC (1986a) Effects of putative α-adrenoceptor antagonists and of other compounds on the loss of the righting reflex and on exophthalmia induced by xylazine in the rat. Drug Dev Res 7:125-140.
13. Colpaert FC (1986b) Maximal magnitude of effect and potency of putative α-adrenoceptor agonists in causing CNS depression, in relaxing muscle and in lowering body temperature in rat. Drug Dev Res 7:209-220.
14. Colpaert FC (1987) Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26:1431-1440.
15. Colpaert FC (1994) Noradrenergic mechanisms in Parkinson's disease: A theory, in Noradrenergic Mechanisms in Parkinson's Disease (Briley M and Marien M eds) pp 127-138, CRC Press, Boca Raton.
16. 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs. Brain Res Bull 26:627-631.
17. Costall B and Naylor RJ (1975) A comparison of circling models for the detection of antiparkinson activity. Psychopharmacologia 41:57-64.
18. Delina-Stula A, Baumann P and Buch O (1979) Depression of exploratory activity of clonidine in rats as a model for the detection of relative pre- and post-synaptic central noradrenergic receptor selectivity of α-adrenolytic drugs. Naunyn-Schmiedeberg's Arch Pharmacol 307:115-122.
19. De Vos H, De Backer JP and Vauquelin G (1991) Efaroxan (RX 821037) is a potent and selective alpha2-adrenoceptor antagonist in human frontal cortex membranes. Neurochem Int 18:137-140.
20. Fallon SH and Moore RY (1978) Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol 180:545-580.
21. Flamez A, De Backer JP, Czerwiec E, Ladure P and Vauquelin G (1997) Pharmacological characterization of I1 and I2 imidazoline receptors in human striatum. Neurochem Int 30:25-29.
22. Freed CR and Yamamoto BK (1985) Regional brain dopamine metabolism: A marker for the speed, direction and posture of moving animals. Science 229:62-65.
23. Friedman P (1991) GB-STAT: Computer aided statistics & graphics, Ver 3.0. Dynamic Microsystems. Inc., Silver Spring.
24. Gerlach M and Riederer P (1996) Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041.
25. Grant JA and Scrutton MC (1980) Interaction of selective α-adrenoceptor agonists and antagonists with human and rabbit blood platelets. Br J Pharmacol 71:121-134.
26. Grenhoff J and Svensson TH (1988) Clonidine regularizes substantia nigra dopamine cell firing. Life Sci 42:2003-2009.
27. Haeusler G (1974) Clonidine-induced inhibition of sympathetic nerve activity: No indication for a central presynaptic or an indirect sympathomimetic mode of action. Naunyn-Schmiedeberg's Arch Pharmacol 286:97-111.
28. Hertel P, Nomikos GG, Schilström B, Arborelius L and Svensson TH (1997) Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: Role of α2-adrenoceptor antagonism. Neuropsychopharmacology 17:44-55.
29. Hervé D, Blanc G, Glowinski J and Tassin JP (1982) Reduction in DA utilization in the prefrontal cortex but not in the nucleus accumbens after selective destruction of noradrenergic fibers innervating the ventral tegmental area in the rat. Brain Res 237:510-516.
30. Hornykiewicz O and Kish SJ (1986) Biochemical pathophysiology in Parkinson's disease. Adv Neurol 45:19-34.
31. Hudson JL, van Horne CG, Strömberg I, Brock S, Clayton J, Masserano J, Hoffer BJ and Gerhardt GA (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626:167-174.
32. Jones BA and Moore RY (1977) Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res 127:23-53.
33. 2-adrenoceptors. J Psychopharmacol 10(Suppl 31:2-5.
34. Levitt P and Moore RY (1979) Origin and organisation of brainstem catecholamine innervation in the rat. J Camp Neurol 186:505-528.
35. Marien M, Lategan A and Colpaert FC (1994) Noradrenergic control of striatal dopamine release, in Noradrenergic Mechanisms in Parkinson's Disease (Briley M and Marien M eds) pp127-138, CRC Press, Boca Raton.
36. 2-adrenoceptor antagonists (+)-efaroxan and (±)-idazoxan on quinolinic acid-induced lesions of the rat striatum. Soc Neurosci Abst 22:1908.
37. 2 agonists and antagonists. Brain Res 562:216-224.
38. Mavridis M, Degryse AD, Lategan AJ, Marien M and Colpaert FC (1991b) Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41:507-523.
39. McMillen BA (1983) CNS stimulants: Two distinct mechanisms of action for amphetamine-like drugs. Trends Pharmacol Sci 9:429-432.
40. Medgett IC, McCulloch MW and Rand MJ (1978) Partial agonist action of clonidine on prejunctional and postjunctional alpha-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 304:215-221.
41. alpha 2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline. J Pharmacol Exp Ther 270:958-972.
42. 3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. J Pharmacol Exp Ther 264:1187-1197.
43. 1-imidazoline sites in bovine adrenal medullary membranes. Naunyn-Schmiedeberg's Arch Pharmacol 348:70-76.
44. Moroni F, Tanganelli S, Antonelli T, Carla V, Bianchi C and Beani L (1983) Modulation of cortical acetylcholine and γ-aminobutyric acid release in freely moving guinea pigs: Effects of clonidine and other adrenergic drugs. J Pharmacol Exp Ther 227:435-440.
45. NRC (National Research Council) (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
46. 2-adrenoceptor antagonists on extracellular dopamine concentrations in rat striatum, in Noradrenergic Mechanisms in Parkinson's Disease (Briley M and Marien M eds) pp 127-138, CRC Press, Boca Raton.
47. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates, 2nd ed., Academic Press, New York.
48. Pellow S, Chopin P and File SE (1985) Are the anxiogenic effects of yohimbine mediated by its action at benzodiazepine receptors? Neurosci Lett 55:5-9.
49. Peyro-Saint-Paul H, Durif F, Pollak P, Bonnet AM, Payen I, Vidailhet M, Plêtan Y and Agid Y (1997) Short term oral administration of idazoxan in mild stable parkinsonian patients treated with L-DOPA. J Pharmacol Clin Ther 1 (Suppl) Abstract: 172.
50. 2-adrenoreceptors. Eur J Neurosci 7:2370-2378.
51. Pycock CJ (1980) Turning behavior in animals. Neuroscience 5:461-514.
52. Pycock CJ, Jenaer PG and Marsden CD (1977) The interaction of clonidine with dopamine-dependent behavior in the rodent. Naunyn-Schmiedeberg's Arch Pharmacol 297:133-141.
53. 2-adrenoceptors. J Pharmacol Exp Ther 227:421-428.
54. Ruzicka E, Ladure P, Roth J, Jech R, Mecir P and Peyro-Saint-Paul H (1997) Efficacy and safety of efaroxan, an alpha-2 adrenoceptor antagonist, in Parkinson's disease: An oral short-term study. Data presented at the XIIth International Symposium on Parkinson's Disease; 1997 Mar 23-26; London: 463.
55. 2-adrenoceptor agonist. Mol Pharmacol 51:36-46.
56. Schwarting RKW and Husten JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol. 50:275-331.
57. Silverman PB (1993) On-off effects of dopamine receptor agonists in the hemiparkinsonian rat. Eur J Pharmacol 242:31-36.
58. Stoof JC, Vermeulen RJ, Van Royen EA, Drukarch B, Voorn P, Wolters EC and Groenewegen HJ (1996) Dopaminergic systems and Parkinson's disease: Some latest developments in pathogenetic, diagnostic and pharmacotherapeutic investigations. Neurosci Res 18:133-142.
59. Svensson A, Carlsson ML and Carlsson A (1995) Crucial role of the accumbens nucleus in the neurotransmitter interactions regulating motor control in mice. J Neural Transm 101:127-148.
60. Taghzouti K, Le Moal M and Simon H (1991) Suppression of noradrenergic innervation compensates for behavioral deficits induced by lesion of dopaminergic terminals in the lateral septum. Brain Res 552:124-128.
61. Taasin JP, Trovero F, Blanc G, Hervé D and Glowinski J (1994) Interactions between noradrenaline and dopamine neurotransmission in the rat prefrontal cortex and their consequences on dopaminergic subcortical function, in Noradrenergic Mechanisms in Parkinson's Disease (Briley M and Marien M eds) pp107-125, CRC Press, Boca Raton.
62. 2-adrenoceptor antagonist, (+)-efaroxan, enhances acetylcholine release in the rat cortex in vivo. Eur J Pharmacol 277:113-116.
63. 2-adrenoceptor agonists and antagonists. J Neurochem 88:778-785.
64. Ungerstedt U (1971) Post-synaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand 367:69-93.
65. 2-agonist binding sites in the rat and human central nervous system: Analysis of some functional and anatomic correlates of the pharmacological effects of clonidine and related adrenergic agents. Brain Res Rev 69:69-86.
66. 2-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves. Br J Pharmacol 109:655-660.
67. Wikberg JES, Uhlen S and Chhajlani V (1991) Medetomidine stereoisomers delineate two closely related subtypes of idazoxan (imidazoline) I-receptors in the guinea-pig. Eur J Pharmacol 193:335-340.
68. 2-Adrenergic control of dopamine overflow and metabolism in mouse striatum. Eur J Pharmacol 339:113-119.
69. 2-adrenergic drugs on cortical high voltage spindles in rats. Eur Neuropsychopharmacol 4:535-538.
70. 2-adrenoceptors in the rat hippocampus after long-term desipramine treatment. Eur J Pharmacol 294:565-570.